This study sought to evaluate the outcome and prevalence of viral endomyocardial infection after cardiac transplantation.
cardiac graft loss have been identified (2, 3) , the majority of which are not amenable to modification. Viral allograft infection is a potential risk factor amenable to therapy and deserves further evaluation.
Viral myocarditis of the native heart is an established etiology for dilated cardiomyopathy (4, 5) . We have hypothesized that viral infection of the post-transplant heart is also detrimental. The histologic diagnostic criteria for myocarditis, the Dallas criteria, rely heavily on the combination of inflammatory infiltrate, myocyte necrosis, edema, and fibrosis (6) . Cardiac transplant rejection, as defined by the International Society of Heart and Lung Transplantation (7), appears similar to the criteria for myocarditis. It is possible, therefore, to speculate that the 2 disorders are related, both triggered by viral infection. Viral genome has been detected in the cardiac allograft after transplantation (8 -11) and is associated with an increased risk for rejection and graft loss (8, 11) . A similar association has also been shown in lung and renal transplant recipients (12, 13) .
Viral infections, especially cytomegalovirus (CMV), have been implicated in the pathogenesis of coronary atherosclerosis in the general population and transplant coronary artery disease in cardiac transplant patients (14 -16) . Treatment with ganciclovir and anti-CMV immunoglobulin decreases the risk of transplant coronary artery disease (TCAD) in cardiac transplant recipients with systemic CMV infection (17, 18) . Intravenous immunoglobulin (IVIG) therapy for acute viral myocarditis is common in many centers, based on studies suggesting a beneficial role of IVIG in these patients (19, 20) . In addition, IVIG has been utilized for its immunomodulatory effects in transplant recipients with viral infection as well as other conditions with possible immune-mediated, infectious agent-triggered etiologies (21, 22) .
In this study, we compared the outcomes of cardiac transplant patients with viral polymerase chain reaction (PCR)-positive versus -negative endomyocardial biopsies (EMBs), as well as the outcomes of IVIG-treated PCRpositive patients with that of PCR-positive, IVIGuntreated counterparts.
Methods
Patient cohort. All consecutive cardiac transplant patients followed in Texas Children's Hospital between June 1, 1999, and November 30, 2004, were eligible for selection. Five patients who had undergone cardiac transplantation in another institution and 2 patients who did not undergo any EMBs due to lack of vascular access or clinical instability were excluded. The final study cohort consisted of 94 patients. Seven patients transferred care to another institution prior to completion of the study and were censored after the last day of patient encounter.
Baseline recipient and donor characteristics, immunosuppressive regimen, and post-transplant patient course data were retrospectively collected from hospital records. The study cohort was divided into 2 exposure groups, based on the presence or absence of viral genome in their EMBs. An overview of the study design and analysis is given in Figure 1 . EMB, histopathology, and PCR. Serial surveillance right ventricular EMBs were performed as per an established schedule (Online Table 1 ). Patients with concern for acute graft dysfunction also underwent nonscheduled EMBs. Histological grading of biopsy specimens was performed according to Texas Heart Institute and International Society of Heart and Lung Transplantation criteria (7, 23) . PCR analysis of all EMBs for the presence of adenovirus, parvovirus B19, Epstein-Barr virus (EBV), CMV, and enteroviral genomes was performed by individuals who were blinded to the clinical course, as previously described (11) . Detection of viral genome in EMBs was considered diagnostic of viral endomyocardial infection (current or past) for purposes of this study. Outcomes. The patient cohort was followed for the outcomes of all-cause graft loss, advanced TCAD, and acute rejection (AR) until June 30, 2005. All patients underwent baseline coronary angiograms 3 months after transplantation followed by annual screening coronary angiograms, starting from 1 year after transplantation. TCAD was diagnosed on the basis of either the coronary angiograms or the histological evaluation of the cardiac allograft in patients who suffered graft loss. Severity of TCAD was graded as defined by Cardiac Transplant Research Database (CTRD) criteria (Online Table 2 ) (24) and classified as advanced TCAD if criteria for moderate or severe TCAD were met. AR was diagnosed by the treating physicians in conjunction with the cardiac pathologist on the basis of the clinical picture and histopathology results of EMBs. All rejection episodes were treated by pulse steroid therapy plus a change in short-and/or long-term immunosuppressive therapy. IVIG treatment. From November 2002 to November 2004, the management of viral endomyocardial infection in cardiac transplant patients at our institution included administration of a single dose of 1 g/kg IVIG, given after each PCR-positive biopsy, either during the same hospital visit or on a follow-up visit. All patients with any viruspositive EMBs were eligible to receive IVIG. This treatment protocol was discontinued after November 2004 due to an institutional restriction on off-label use of IVIG, triggered in part by a shortage of IVIG supplies nationally. As a subgroup analysis, outcome data from the viral PCRpositive IVIG-treated patients were compared with their IVIG-untreated viral PCR-positive counterparts (historic or concurrent) as controls. Table 1 . Differences between the 2 groups included; the PCRpositive group had a higher mean recipient age (p ϭ 0.007) and weight (p ϭ 0.002) at transplant, higher mean donor age (p ϭ 0.004), higher number of retransplants (p ϭ 0.02), more patients with viral genome detected in the explanted heart (p ϭ 0.03), and more patients on left ventricular assist device/extracorporeal membrane oxygenation at transplant (p ϭ 0.05). There was no difference in the pattern of immunosuppression between the PCR-positive and -negative groups. The PCR-positive and -negative groups were similar with respect to the initial triple-drug therapy combination. There was no statistically significant difference in the 2 groups with respect to the percentage of patients in whom azathioprine or mycophenolate was discontinued and immunosuppression transitioned to a combination of prednisone and a calcineurin inhibitor alone. No adjustments in immunosuppression were made if virus was detected in the myocardium.
Of the 94 patients in the study cohort, 24 underwent transplantation before the onset of the study in June 1999. Of these, 19 remained PCR-negative and 5 became PCR-positive during the course of the study. At their entry into the study, the mean time from transplantation was 5.19 years in the 19 PCR-negative patients and 3.84 years in the 5 PCR-positive patients. The average follow-up period after transplantation was 4.99 years in the PCR-negative patients and 3.64 years in the PCRpositive patients. Viral PCR results of EMBs. PCR was performed on 928 serial EMBs from the 94 study patients. Viral genome was Virus subtype and outcome. After adjusting for viral subtypes using Cox regression, adenoviral (p ϭ 0.03) and EBV (p ϭ 0.002) endomyocardial infections were associated with decreased graft survival (Fig. 2F) . The risk for graft loss was 4.1 (95% CI: 1.13 to 14.73) times higher in the adenovirus-positive patients and 8.5 (95% CI: 2.18 to 33.56) times higher in the EBV-positive patients compared with the PCR-negative patients. However, the predicted graft survival for parvovirus endomyocardial infection was similar to that of PCR-negative patients. This was confounded by the fact that the majority (17 of 23, 74%) of the parvovirus-positive patients received IVIG therapy after a PCR-positive biopsy, which could have had a beneficial effect on the outcome. After adjusting for viral subtypes using Values are n, n (%), or mean Ϯ SD unless otherwise indicated. CHD ϭ congenital heart disease; CMV ϭ cytomegalovirus; DCM ϭ dilated cardiomyopathy; EBV ϭ Epstein-Barr virus; ECMO ϭ extracorporeal membrane oxygenation; HLA ϭ human leukocyte antigen; ICU ϭ intensive care unit; LVAD ϭ left ventricular assist device; NS ϭ not significant; PCR ϭ polymerase chain reaction; PCWP ϭ pulmonary capillary wedge pressure; PSP ϭ pulmonary systolic pressure; PVR ϭ pulmonary vascular resistance; RCM ϭ restrictive cardiomyopathy; UNOS ϭ United Network for Organ Sharing.
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of the 20 IVIG-treated patients and 8 (47%) of the 17 IVIG-untreated patients suffered graft loss. Graft survival from the date of transplant (p ϭ 0.09, log-rank) (Fig. 3A) , and graft survival after becoming PCR-positive (p ϭ 0.06, log-rank) (Fig. 3B) trended to be better in the IVIG-treated group compared with the IVIG-untreated group. The 3-year survival after becoming PCR-positive was 86% (95% CI: 54% to 96%) in the IVIG-treated patients, compared with 33% (95% CI: 8% to 62%) in the IVIG-untreated patients (p ϭ 0.03, log-rank). Freedom from advanced TCAD, measured from the time of transplant, was better in the IVIG-treated patients (p ϭ 0.05, log-rank) (Fig. 3C) . The onset of advanced TCAD after becoming PCR positive was delayed in the IVIGtreated patients compared with the untreated control group (p ϭ 0.03, log-rank) (Fig. 3D) . The 3-year freedom from advanced TCAD after the first PCR-positive biopsy was 82% (95% CI: 24% to 97%) in the IVIG-treated patients compared with 45% (95% CI: 11% to 75%) in the IVIGuntreated patients (p ϭ 0.03, log-rank). IVIG therapy did not affect the number of AR episodes after becoming PCR positive. In addition, it did not seem to help in the clearance of viral genome. Viral genome was amplified from the follow-up biopsy in 48% of the IVIG-treated biopsies and 37% of the IVIG-untreated biopsies (p ϭ NS, chi-square). A valid comparison of virus-free time after a PCR-positive biopsy could not be performed as the follow-up biopsies were obtained at varying time intervals. 
Discussion
In this retrospective single-institution study, we show that occult viral endomyocardial infection (diagnosed by viral PCR-positive EMBs) after transplantation is common in pediatric cardiac transplant patients and is associated with premature graft loss. We also show that viral endomyocardial infection is an independent risk factor for premature loss of the cardiac allograft and appears to mediate this effect through premature development of advanced TCAD. The greatest risk for developing viral endomyocardial infection is in the first year after transplantation (which is also the time of maximal immunosuppression), parvovirus B19 infection being the most common, followed by adenovirus and EBV. Parvoviral B19 infection has a tendency for chronicity. IVIG therapy may improve graft survival and delay onset of advanced TCAD in the viral PCR-positive patients and merits further evaluation. Study limitations. Our study is limited by its retrospective nature and low number of events, raising concerns for inability to compensate for all baseline differences and overfitting. The possibility that some of the patients classified as viral PCR-negative could have had undetected transient viral endomyocarditis may have resulted in an inadvertent selection bias and inflated or deflated the true strength of association between viral endomyocardial infection and an adverse outcome. However, these results replicate our findings from a prior prospective trial performed in a completely different cohort of pediatric cardiac transplant patients followed in a completely different institution and, hence, are less likely to represent an alpha error (11) . The IVIG therapy subgroup analysis is limited by an uncontrolled, retrospective analysis, small sample size, and unequal distribution of viral subtypes in the IVIG-treated and -untreated groups. The prevalence of advanced TCAD was much higher in our patient cohort compared with recently published prevalence rates in pediatric heart transplant recipients in a multi-institutional study, with a 17% probability of devel- 
